FBP1 and hepatocellular carcinoma: It has been demonstrated that bortezomib suppresses the apoptotic activity of HCC by inhibiting FBP1 degradation and modulating the Warburg effect in HCC, thus inhibiting HCC proliferation, migration, and invasion, but further clinical trials are needed to prove its value in clinical application [103].